The French startup raised a €20M Series A led by Critical Path Ventures and Bpifrance to fund clinical trials of its focused ultrasound treatment for treatment-resistant depression. SonoMind uses a patient-specific acoustic meta-lens to direct low-intensity ultrasound toward deep brain structures that TMS and tDCS cannot easily reach. Preliminary results from Sainte-Anne Hospital showed more than 60% reduction in symptom severity after five consecutive daily sessions; market authorization is targeted by 2029.